Applied Therapeutics (NASDAQ:APLT)
- Number of Upgrades from Top-Ranked Analysts
- 3 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.5
- Ratings Breakdown
- 3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $6.10 (1,678.9% Upside)
About Applied Therapeutics
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
More about Applied Therapeutics
Recent Analyst Ratings
While no one can say for sure that these will be the ten best penny stocks next year, Wall Street's top analysts are giving them high price targets, "buy" ratings and are telling their clients to acquire shares.
More Investing Slideshows:
